2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5020 Selective targeting of cancer associated PCNA (caPCNA) reduces OXPHOS across acute myeloid leukemia (AML) stem cell states

Amanda Blackmon, DO, Le Xuan Truong Nguyen, PhD2, Brian John Ball, MD, MS3, Jianying Zhang, PhD4, Marjorie Robbins, PhD5, Long Gu6, Robert Hickey, PhD7, Jeffrey Tyner, PhD8, Linda Malkas9, Guido Marcucci, MD10
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, Translational Genomics Research Institute, Phoenix, Arizona, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
8 Oregon Health & Science University, Portland, Oregon, United States
9 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States

Responses to azacitidine (AZA)/venetoclax (VEN) in AML are 60–70%, however the majority relapse due to persistence of leukemia stem cells (LSCs). Analyses of bone marrow (BM) and peripheral blood (PB) samples from VEN/AZA-treated patients revealed heterogeneous LSC populations with primitive (pLSCs) and monocytic (mLSCs) subtypes. pLSCs, typically characterized as CD34+CD38−, rely predominantly on amino acid (aa)-fueled oxidative phosphorylation (OXPHOS) and are VEN-sensitive (sVEN) as BCL-2 supports their mitochondrial fitness. In contrast, mLSCs, defined by the CD34−CD4+CD11b−CD14−CD36− immunophenotype, rely on fatty acid oxidation (FAO)-fueled OXPHOS and are more VEN-resistant (rVEN). LSCs dynamically evolve under treatment pressure but remain dependent on mitochondrial fitness and OXPHOS for survival, yet OXPHOS inhibitors showed toxicity and off target activity in normal hematopoietic stem cells (HSCs) and other tissues. Herein, we describe a novel cancer-associated (ca) isoform of proliferating cell nuclear antigen (PCNA), that when inhibited specifically disrupts OXPHOS and mitochondrial fitness across AML LSC states, while sparing normal HSCs.

Canonical PCNA is involved in nuclear functions, regulating transcription–replication conflicts (TRC) by acting as a scaffold, coordinating DNA replication and repair. In contrast, we found that caPCNA is restricted to cancer cells (including AML blasts and LSCs) and localizes and functions beyond the nucleus. caPCNA is generated through post-translational modifications exposing a surface configuration within the PIP-box binding region (L126–Y133), creating a cancer-specific binding pocket enabling noncanonical functions. Using a caPCNA specific antibody, we demonstrated by immunoblotting (IB) and immunohistochemistry (IHC) the enrichment of caPCNA in AML blasts, pLSCs and mLSCs (each n=5; from patients with FLT3-WT, FLT3-ITD, inv(16), TP53-WT, and TP53-MUT), but not in normal HSCs, whereas only canonical PCNA was expressed in HSCs.

RNA-seq cannot distinguish between canonical PCNA and caPCNA, nevertheless PCNA expression comprising both canonical and ca isoforms is higher in AML than normal HSCs. Analysis of the BEAT AML database shows PCNA transcripts are increased in AML, including high-risk subsets (TP53-MUT, n=60; p=2.3×10⁻⁵) and therapy-resistant disease (rVEN, n=11 versus sVEN, n=8; p=0.0036), and associated with shorter overall survival (OS; high vs low PCNA expression, n=53 each; p=0.054). We hypothesized that higher expression of PCNA in AML is due mainly to generation of caPCNA. In fact, enforced PCNA expression via plasmid transduction induced caPCNA in primary AML blasts but not normal HSCs (n=3 each). Of note, IB of CD34⁺CD38⁻ LSC-enriched cells showed caPCNA is highly expressed in AML, including TP53-MUT and rVEN AML. Analysis of LSC state signatures in BEAT AML demonstrated that PCNA levels associate with GMP-like, promonocyte-like, and early erythroid-like signatures – cell states linked to rVEN.

We identified AOH1996 (AOH), a first-in-class oral small-molecule inhibitor of caPCNA. AOH disrupts caPCNA–OPA1 interaction, promoting MARCH5-mediated OPA1 ubiquitination and degradation, resulting in mitochondrial fission, suppression of FAO/OXPHOS, and downregulation of BCL-2 family proteins and other key metabolic regulators (NRF2 and CPT1B) in AML LSCs, while sparing normal HSCs. These findings identify caPCNA as a central regulator of mitochondrial fitness across both sVEN and rVEN LSC states.

AOH complements and extends VEN/AZA activity by suppressing mitochondrial fitness below the threshold required for survival of both sVEN pLSCs and rVEN mLSC states. In vitro treatment of LSC-enriched primary CD34⁺CD38⁻ AML cells treated with AOH exhibited strong synergistic cytotoxicity with VEN/AZA (i.e. AOH/VEN/AZA (triplet); Max Synergy Score: 24.957). FLT3-WT AML PDX models treated with triplet (100 mg/kg AOH twice daily, 100 mg/kg VEN daily, and AZA 2 mg/kg IP every 3 days) showed significantly prolonged survival compared with AOH/VEN or VEN/AZA (median survival: 160 vs. 83.5 and 87.5 days, respectively; P< 0.0001). In 2nd transplant, we showed significantly longer survival extension in mice receiving BM from triplet-treated donors, indicating durable depletion of functional LSCs. The clinical trial of AOH in relapsed/refractory (R/R) AML is ongoing (NCT06763341) and has been well-tolerated thus far, with plans for a triplet trial in R/R AML anticipated in 2027.

Amanda Blackmon, DO: No relevant conflicts of interest to declare.